Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opthea Spon American Depositary Receipts Representing 8 Ord Shs OPT

Alternate Symbol(s):  CKDXF

Healthcare Biotechnology
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).


NDAQ:OPT - Post by User

Opthea Spon American Depositary Receipts Representing 8 Ord Shs
<< Previous
 Bullboard Posts
User Avatar Image
(291)
•••
Post by whytestockson Nov 26, 2024 4:02pm
26 Views
Post# 36332067

Opthea's Wet AMD Program to be Featured at FLORetina 2024

Opthea's Wet AMD Program to be Featured at FLORetina 2024
BREAKING NEWS: $OPT Opthea's Wet AMD Program to be Featured at FLORetina 2024MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, &#x201C;Opthea&#x201D;, the &#x201C;Company&#x201D;), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...OPT - Opthea's Wet AMD Program to be Featured at FLORetina 2024

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities